Seth Stern Email & Phone Number

Menlo Park, CA, US

Nexgen Biotools is solving the library prep bottleneck in nextgen sequencing workflows with novel microfluidics solutions.

Fremont, California, US

Responsible for developing the next iteration of Ultima's clonal amplification technology.

San Diego, CA, US

Worked mainly on adapting Roswell's single-molecule detection technology for DNA sequencing applications.

Since successful completion of proof-of-concept for the microfluidic library preparation project, I have been conducting R&D projects aimed at improving GenapSys core DNA sequencing technology. This work has involved development of improved sequencing methods and chemistry that are compatible with GenapSys CMOS chips.

I have been responsible for the development of innovative microfluidic chips and supporting instrumentation to implement NGS library preparation. This has involved creation of a novel digital pneumatic architecture and low cost manufacturing methods to produce devices and systems that are a suitable match for GenapSys’ compact, low-cost DNA sequencing.

Athena is exploiting the latest developments in robotics to produce a new liquid-handling laboratory robot that provides radically increased flexibility and programming ease at an affordable price. Athena's technology provides access to virtually the full range of standard molecular biology tools and methods including: microliter-level liquid-handling.

I worked on their novel and innovative DNA sequencing technology based on electronic detection of polymerase activity. I was mainly occupied with characterization and debugging of the sensor chip using a microfluidic breadboard system and electronic instruments for measuring small currents.

IntegenX has been developing microfluidic chip technology based on pneumatically actuated on-chip pumps and valves constructed with PDMS membranes. I worked on a number of successful and interesting projects there that involved both my molecular biology and engineering skills, beginning with development of a microfluidic chip for mRNA amplification in.

US

I was mainly involved in two activities: first, invention of methods and devices for automated, miniaturized mRNA amplification, which involved successful application of for a Phase I SBIR grant to the National Institute of General Medical Sciences (NIGMS), and second, development of methods and chemistries for automated and miniaturized total RNA, polyA+.

Waltham, MA, US

I was involved with invention and development of miniaturized, sample-to-answer nucleic acid processing systems comprising polymeric, laminated microfluidic chips for nucleic acid purification with nanoporous aluminum oxide membranes, and thermocycling for RT-PCR. These chips interfaced with LabVIEW-driven valves, syringe pumps, and epi-fluorescence.

ChemAutomaton proposed development of technologies for automated, massively parallel, target-directed small molecule (ligand) discovery and optimization, based on iterated DNA-programmed organic synthesis, target-specific selection, and PCR amplification. Such methods represent an alternative to traditional medicinal chemistry and high-throughput screening.

Glendale, California, US

Caliper was developing a microfluidic chip for real-time PCR based on a novel thermocycling strategy that involved joule heating of PCR buffer in microfluidic channels. I was first able to successfully conduct proof-of-concept experiments, and I then designed a microfluidic "sipper chip" that could detect SNPs in gDNA. I subsequently developed methods for.

For IBIS Therapeutics: Identification of potential antimicrobial drug targets in ribosomal RNA and design of “RNA analogs" useful in high-throughput screening. I identified sub-domains in bacterial 16S and 23S ribosomal RNA with potential utility as targets for small molecule protein synthesis inhibitors and designed small RNA analogs for use in in-vitro.

My postdoctoral research at Cold Spring Harbor Laboratory was concerned with the human homeodomain- (actually POU domain-) containing transcription factor Oct-1. As an assistant professor, I successfully competed for and competed a NIH R01 research grant for research on Oct-1—VP16 interactions. These studies involved the development of a yeast two-hybrid.

Cold Spring Harbor, New York, US

Successfully competed for and competed an NIH postdoctoral training grant. I was able to show that the viral transcription factor VP16 recognizes amino acids in the homeodomain (DNA-binding domain) of the human homeodomain protein Oct-1, an unexpected and significant observation at the time that resulted in several publications including the leading.

Santa Cruz, CA, US

My PhD research in Professor Harry Noller's lab at UCSC concerned protein--RNA interactions in the 30S subunit of the E. coli ribosome. I participated in the development of new chemical/enzymatic structure probing and footprinting methods that relied on reverse transcription of modified RNA. Using these methods we were able to localize binding sites for.

Santa Clara, California, US

I was very fortunate to assist in the development of Intel's CMOS process technology (P444). I was involved with: validation of design rules for new device fabrication technology, characterization of the performance of CMOS static RAM test vehicle, full-die simulation (using Intel’s proprietary SPICE derivative) of a 64K CMOS dynamic RAM, characterization.

Phd, Molecular Biology Of Rna

Bsee, Electrical Engineering